Keynote Presentation: Glaucoma Management in the COVID-19 Hotspot

Speaker: Dr. Matteo Sacchi, MD, Head of Glaucoma Service, Ospedale San Giuseppe, Clinica Oculistica, Università degli Studi di Milano, Italy

A Phased Approach in Restarting Glaucoma Practice After COVID-19 Pandemic in a Public University Hospital

Speaker: Dr. Marta Pazos, MD, PHD, Glaucoma Senior Specialist Hospital Clínic of Barcelona, Ophthalmology Insitute (ICOF), Barcelona, Spain

The glaucoma department at Hospital Clínic of Barcelona deferred almost 1,000 glaucoma outpatient attendances over the course of COVID-19 lockdown. During the confinement, careful review of patient records and directed telephone anamnesis were made to assess risk stratification. Phased attention was scheduled into three different periods of time. Integrated clinical, structural, and functional data obtained in a remote decision setting was used to adapt the glaucoma practice to post COVID-19 challenges.

Viscocanaloplasty: A Surgical Approach for Glaucoma in Highly Myopic Eyes & SITA Faster

Speaker: Dr. Aritz Urcola, MD, PhD, Head of Glaucoma Unit, Hospital Universitario Araba, Miranza Begitek (San Sebastián), Miranza Okular (Vitoria), Spain

Outcomes of two clinical studies are presented: A) Viscocanaloplasty in high myopic eye with analysis of IOP reduction, postoperative hypotensive medication and incidence of complications B) Comparison of SITA Faster with SITA Standard and SITA Fast strategies to determine preferred visual field test used during COVID-19 pandemic

Glaucoma Diagnostics in COVID-19 and Beyond

Speakers: Dr. Ike Ahmed (Prism Eye Institute) and Dr. Matt Schlenker, Canada

Ike Ahmed, MD and his team at the Prism Eye Institute have actively been supporting their peers during these challenging times through interactive broadcasts and webinars. Dr. Ahmed will provide an overview of OCT utilization in his practice and how best to prioritize OCT usage post COVID-19, when your backlog of patients are allowed to return to the practice for in-person consultations/exams.

Technology Evolution in My Practice

Speaker: Dr. Maria da Luz Freitas, MD, FEBOS Glaucoma, Clínica Oftlamológica Dr. Queiroz Marinho, Porto, Ophthalmology Department of Hospital da Luz Arrábida, Portugal

Retrospective view on glaucoma management from 1997 till today. Various approaches to diagnosing and managing glaucoma patients were developed during different phases of the practice. Clinical cases where technology made a difference will be presented.

Practical Benefits of 24-2C and Desired Enhancements for the Pattern

Speaker: Dr. Eva Vrbka, MD, Smartlook AG, Specialist Center for Ophthalmology, Private Practice/Owner, Pallas Clinical Centers Attending Ophthalmologist, Switzerland

The 24-2C pattern frequently shows damage in the paracentral area that has not been detected or was underestimated using the 24-2 or 30-2 pattern. In order to confirm such findings, sometimes patients are reexamined soon after this “initial” determination of paracentral losses. But there are also patients that show defects on the RNFL analysis which are not reflected in the 24-2C and indicate that more peripheral areas are affected.

Glaucoma: 2020 Poster Highlights on Latest Innovations from ZEISS

ZEISS R&D

A quick look at research and technological advancements in eye care provided by ZEISS's top scientists, clinicians and engineers. These select posters include the leading edge innovations using SITA Faster 24-2C, CLARUS® Ultra-widefield imaging, and CIRRUS® OCT.

Structure-Function Relationship in Glaucoma

Speaker: Dr. Javier Moreno-Montanes, MD, PhD, Ophthalmology Department, University of Navarra Clinic Professor of Ophthalmology, University of Navarra, Faculty of Medicine, Spain

The analysis of the relationship between structure and function in glaucoma is necessary to understand both the severity and the progression of the disease. The structure-function agreement of the eyes in different stages of glaucoma was evaluated based on the 6 structure-function zones of the Garway-Heath map and by categorizing the cases into stages according to the Glaucoma Staging System (GSS).